Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension

Current Hypertension Reports
Steven G Chrysant, George S Chrysant

Abstract

Cardiovascular disease (CVD) remains the leading cause of death in the developed countries and is estimated to be the leading cause of death in the developing countries by the year 2030. The cause for this rise in CVD is the increase in the major CVD risk factors (CVRFs) like hypertension, obesity, diabetes, and hyperlipidemia, which account for 80 % of all CVD deaths worldwide. In order to prevent the increase in CVD, it has been proposed to develop a low-cost polypill containing four to five generic drugs with known effectiveness in the reduction of the CVRFs. This polypill has now been tested in several recent studies for the primary and secondary prevention of CVD and stroke with fairly good results. A Medline search of the English language literature between 2011 and 2015 resulted in the identification of 15 studies with pertinent findings. These findings together with collateral literature will be discussed in this review.

References

Nov 20, 2002·Archives of Internal Medicine·Malcolm R LawNicholas J Wald
Jun 28, 2003·BMJ : British Medical Journal·N J Wald, M R Law
Mar 17, 2009·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Kornelia KotsevaUNKNOWN EUROASPIRE Study Group
Mar 26, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Anil PatelBhaswat S Chakraborty
Jul 14, 2011·PloS One·Gwendolen M RodgersLesley J Morrell
Nov 8, 2011·European Journal of Preventive Cardiology·Andrew R H DaltonAzeem Majeed
Jul 21, 2012·PloS One·David S WaldNicholas J Wald
Sep 5, 2013·JAMA : the Journal of the American Medical Association·Simon ThomUNKNOWN UMPIRE Collaborative Group
Mar 29, 2014·European Journal of Preventive Cardiology·Anushka PatelUNKNOWN Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration
Jul 6, 2014·The American Journal of Cardiology·Steven G Chrysant, George S Chrysant
Jul 25, 2014·The American Journal of Medicine·Shira BezalelZev Moshe Sthoeger
Sep 7, 2014·Journal of the American College of Cardiology·José M CastellanoValentin Fuster
Dec 17, 2014·The Medical Journal of Australia·Tracey-Lea LabaStephen Jan
Aug 12, 2015·PLoS Medicine·Mark D Huffman

❮ Previous
Next ❯

Citations

Apr 21, 2016·The Journal of Clinical Hypertension·Steven G Chrysant, George S Chrysant
Dec 17, 2016·Journal of Diabetes and Metabolic Disorders·Shirin Hasani-Ranjbar, Hanieh-Sadat Ejtahed
Mar 17, 2018·Therapeutic Advances in Cardiovascular Disease·Patricio López-JaramilloJohanna Otero
Mar 20, 2018·American Journal of Hypertension·Koon Teo, Salim Yusuf
Oct 9, 2018·Expert Opinion on Pharmacotherapy·Beata FranczykJacek Rysz
May 15, 2019·International Journal of Environmental Research and Public Health·Moongu SongHyunsik Kang
Sep 1, 2016·Current Opinion in Lipidology·Laxmi N Rao Bondugulapati

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

© 2022 Meta ULC. All rights reserved